What is the efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes?
The efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes was evaluated in the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) study. The study found that atorvastatin reduced the risk of major cardiovascular events (including nonfatal myocardial infarction, coronary heart disease death, and stroke) in subjects with type 2 diabetes. The study also showed that atorvastatin was well-tolerated and had no significant adverse effects.  